RAD51 and breast cancer: As a comparison, we included the analysis of RAD51 foci in primary tumor samples from patients with untreated breast cancer with germline PVs in BRCA1, BRCA2, and PALB2, which showed a high prevalence of HRD (92.2% [95 of 103]), as expected (Figure 1B).